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Background
Subcutaneous allergen-specific immunotherapy (SCIT) is
a valuable treatment option for patients with controlled
mild to moderate allergic asthma However, SCIT is con-
traindicated for patients with severe persistent asthma
due to a potential systemic allergic reaction. Several stu-
dies in adolescents and adults with persistent allergic
rhinitis and moderate persistent allergic asthma have
shown that SCIT is better tolerated when combined
with. Nevertheless, no previous studies have been con-
ducted in children and adolescents with severe asthma
to assess the safety and efficacy of a combination treat-
ment of SCIT and omalizumab.
Methods
We report here the observations of six patients, aged 11
to 21 years, with severe persistent asthma controlled by
omalizumab as add-on therapy who received SCIT
under a cluster protocol during omalizumab treatment
and then SCIT maintenance alone after discontinuation
of omalizumab.
Results
Although no patients experienced severe exacerbation, one
patient had to stop SCIT after one month of treatment
because of uncontrolled asthma. For the five remaining
patients, asthma control continued to improve during the
combined treatment with SCIT and omalizumab (median
time duration = 8 months) despite a decrease in mainte-
nance treatment for all of them. SCIT was continued
alone for a median time of 25.5 months and was well tol-
erated. For these patients, asthma was totally controlled
and therapeutic levels of maintenance treatment could be
further reduced
Conclusion
Pretreatment by omalizumab for patients with persistent
severe allergic asthma seems to improve the safety and
probably also the efficacy of SCIT. These results open
up perspectives of SCIT for children suffering from
severe allergic asthma. However,the primary outcomes
of these observations are not included in a standardized
protocol and will require further confirmation by pro-
spective double blind studies.
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